Cancer Control最新文献

筛选
英文 中文
Clinicopathological Features and Prognoses of Patients With Splenic Metastases From Breast Cancer: A Single-Centre, Retrospective Study. 乳腺癌脾转移患者的临床病理特征和预后:一项单中心回顾性研究。
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 DOI: 10.1177/10732748241310578
Xiaofeng Xie, Mingrui Ma, Xue Bai, Jing Hu, Haijie Zheng, Xiongqi Guo, Jiayi Huang, Xuelian Chen, Liping Chen, Xiaofeng Lan, Lin Song, Caiwen Du
{"title":"Clinicopathological Features and Prognoses of Patients With Splenic Metastases From Breast Cancer: A Single-Centre, Retrospective Study.","authors":"Xiaofeng Xie, Mingrui Ma, Xue Bai, Jing Hu, Haijie Zheng, Xiongqi Guo, Jiayi Huang, Xuelian Chen, Liping Chen, Xiaofeng Lan, Lin Song, Caiwen Du","doi":"10.1177/10732748241310578","DOIUrl":"10.1177/10732748241310578","url":null,"abstract":"<p><strong>Purpose: </strong>Splenic metastases (SM) from breast cancer (SMBC) are exceedingly rare. To date, the relevant literature is primarily based on pan-tumour species, with only a few studies exploring SM specifically in relation to breast cancer. As such, the present retrospective study explored the clinicopathological characteristics and prognoses of patients with SMBC at the breast care centre of the authors' hospital.</p><p><strong>Methods: </strong>Data from patients newly diagnosed with metastatic breast cancer (MBC) between June 2017 and June 2022 were extracted from medical records at the authors' hospital. Clinicopathological characteristics and their associations with progression-free survival (PFS [time from diagnosis of initial recurrence and/or metastasis to diagnosis of SM]), first overall survival (<sup>1st</sup>OS [time from diagnosis of breast cancer to death or last follow-up visit]), and second overall survival (<sup>2nd</sup>OS [time from diagnosis of SM to death or last follow-up visit]) were analysed in patients with SMBC.</p><p><strong>Results: </strong>In total, 1009 patients with MBC were identified, of whom 18 (1.7%) had SM. T1 and T2 stages were documented in 15 (83.3%) patients, whereas N2 and N3 were documented in 13 (62.2%). 14 (77.8%) patients were oestrogen receptor and/or progesterone receptor positive. A Ki-67 index ≥ 30% accounted for 72.2% (13/18) of cases, and all patients were histological grade II or III. Liver and/or lung metastases were documented in all 18 (100%) patients. Median PFS was 6.3 months. The median <sup>1st</sup>OS and <sup>2nd</sup>OS were 41.8 and 10.6 months, respectively. The number of previous treatment lines before diagnosis of SM was a significant adverse prognostic factor for PFS, and disease-free survival was a significant adverse prognostic factor for <sup>1st</sup>OS.</p><p><strong>Conclusion: </strong>SMBC commonly presents with diffuse multiple organ metastases in the terminal stage of malignancy and has a poor prognosis, which may provide deeper insight into SMBC for clinicians.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241310578"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics, Treatment, and Survival of Male Breast Cancer: A 21-year Retrospective Analysis at a Community Academic Institute in Central Illinois. 男性乳腺癌的特征、治疗和生存:伊利诺斯州中部一个社区学术研究所的21年回顾性分析。
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 Epub Date: 2025-04-20 DOI: 10.1177/10732748251335365
Waqas Azhar, Ricardo Cossyleon, Syeda Fatima Kamal, Kristin Delfino, Kathy Robinson, Krishna Rao
{"title":"Characteristics, Treatment, and Survival of Male Breast Cancer: A 21-year Retrospective Analysis at a Community Academic Institute in Central Illinois.","authors":"Waqas Azhar, Ricardo Cossyleon, Syeda Fatima Kamal, Kristin Delfino, Kathy Robinson, Krishna Rao","doi":"10.1177/10732748251335365","DOIUrl":"https://doi.org/10.1177/10732748251335365","url":null,"abstract":"<p><p><b>Introduction:</b> Male breast cancer is an uncommon disease, representing a fraction of all breast cancer diagnoses. This study examines the characteristics, treatment, and outcomes of males with breast cancer at a community academic institute in central Illinois.<b>Methods:</b> We retrospectively reviewed the medical records of male patients with breast cancer treated between 2000 and 2021. This review focuses on patient demographics, tumor characteristics, treatment modalities, and recurrence and survival rates. We evaluated the association of epidemiological factors and clinical outcomes with patient age, tumor stage, and grade, as well as tumor hormone receptor status.<b>Results:</b> Our study included 81 male patients, predominantly white, with a median age of 67 years. Most cases presented estrogen receptor-positive (96.1%) and progesterone receptor-positive (93.5%) tumors, while only 13.5% had HER-2 neu receptor-positive expression. Staging distribution was 34.6% at Stage I, 47.4% at Stage II, and 17.9% at Stages III/IV among 78 patients. Recurrence occurred in 20.8% of 77 patients, with a 5-year recurrence-free survival rate of 76.2%. The 5-year overall survival rate of all 81 patients was 63.4%. Age and disease stage were significantly associated with mortality (<i>P</i> = .041 and <i>P</i> = .0028, respectively).<b>Conclusion:</b> Our findings align with national trends in male breast cancer demographics and outcomes, with comparable survival statistics. Increased awareness and targeted research are critical to improving management and prognosis for this patient population. Further studies are necessary to elucidate the molecular basis of male breast cancer and to refine treatment guidelines.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251335365"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Moderate-Hypofractionated Radical Radiotherapy for Early-Stage Prostate Cancer: A Propensity Score Matching Analysis Comparing Dose Fractionation Patterns. 中度低分割放射治疗早期前列腺癌:比较剂量分割模式的倾向评分匹配分析。
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 Epub Date: 2025-04-12 DOI: 10.1177/10732748251330058
Yinjie Tao, Weishi Cheng, Hongnan Zhen, Jing Shen, Hui Guan, Xiaorong Hou, Ke Hu, Fuquan Zhang, Zhikai Liu
{"title":"Moderate-Hypofractionated Radical Radiotherapy for Early-Stage Prostate Cancer: A Propensity Score Matching Analysis Comparing Dose Fractionation Patterns.","authors":"Yinjie Tao, Weishi Cheng, Hongnan Zhen, Jing Shen, Hui Guan, Xiaorong Hou, Ke Hu, Fuquan Zhang, Zhikai Liu","doi":"10.1177/10732748251330058","DOIUrl":"https://doi.org/10.1177/10732748251330058","url":null,"abstract":"<p><p>IntroductionThis study evaluates the clinical outcomes, survival benefits, and toxicities of two moderate-hypofractionated radiotherapy (MHRT) patterns, 60 Gy in 20 fractions (60 Gy/20f) and 70 Gy in 28 fractions (70 Gy/28f), in early-stage prostate cancer patients.MethodsThis retrospective study analyzed data from 187 patients diagnosed between 2014 and 2023, using propensity score matching to ensure efficacy assessment accuracy. The primary endpoints reported were overall survival (OS) and disease-free survival (DFS), calculated using Kaplan-Meier analysis. Toxicity and side effects were evaluated using Criteria for Adverse Events v5.0, focusing on the urinary and gastrointestinal (GI) systems.ResultsAfter matching, each of the 60 Gy and 70 Gy groups included 73 patients. The median follow-up duration for all patients was 36.0 months. The OS rates for the 60 Gy and 70 Gy groups were 86.3% and 89.0%, respectively, with 3-year OS rates of 92.4% and 89.0% (<i>P</i> = 0.375). The 3-year DFS rates were 91.0% in the 60 Gy group and 81.0% in the 70 Gy group (<i>P</i> = 0.096), indicating no significant differences between the groups. The incidence of acute Grade 2 or higher urinary toxicities was comparable between the two groups (60 Gy group vs 70 Gy group: 9.6% vs 9.6%, <i>P</i> = 1.0), while the 70 Gy group demonstrated an advantage for late Grade 2 or higher toxicities (60 Gy group vs 70 Gy group: 12.3% vs 2.8%, <i>P</i> = .028). For the GI system, the incidence of acute toxicities was higher in the 60 Gy group, albeit not statistically significant (60 Gy group vs 70 Gy group: 11.0% vs 6.8%, <i>P</i> = .383), while late toxicities were equivalent between the groups (60 Gy group vs 70 Gy group: 1.4% vs 1.4%, <i>P</i> = 1.0).ConclusionBoth MHRT fractionation patterns demonstrate comparable survival outcomes and toxicities in early-stage prostate cancer, suggesting MHRT's viability as a primary treatment. The 60 Gy/20f pattern marginally favored survival, albeit not with statistical significance.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330058"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial-Ethnic Comparisons in Surgical Treatment and Outcomes of Non-Metastatic Renal Cell Cancer in an Equal Access Health System. 平等医疗系统中非转移性肾细胞癌手术治疗和预后的种族比较
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 Epub Date: 2025-04-11 DOI: 10.1177/10732748251334455
Yvonne L Eaglehouse, Sarah Darmon, Craig D Shriver, Kangmin Zhu
{"title":"Racial-Ethnic Comparisons in Surgical Treatment and Outcomes of Non-Metastatic Renal Cell Cancer in an Equal Access Health System.","authors":"Yvonne L Eaglehouse, Sarah Darmon, Craig D Shriver, Kangmin Zhu","doi":"10.1177/10732748251334455","DOIUrl":"https://doi.org/10.1177/10732748251334455","url":null,"abstract":"<p><p>BackgroundAccess to care has been implicated in racial-ethnic disparities in surgical treatment and survival for patients with renal cell carcinoma (RCC) in the United States. We assessed whether there were racial-ethnic disparities in surgery receipt and clinical outcomes of RCC in the equal access U.S. Military Health System (MHS).Materials and MethodsWe used the MilCanEpi database to study a cohort of patients aged 18 and older who were diagnosed with stage I-III RCC between 1998 and 2014. Treatment with nephrectomy was evaluated in Poisson regression models expressed as adjusted incidence rate ratios (AIRRs) with 95% confidence intervals (CIs). Risk of recurrence and all-cause death were estimated using multivariable Cox regression models.ResultsThe study included 1371 non-Hispanic White, 362 non-Hispanic Black, and 177 Hispanic patients. Black patients had lower rates of nephrectomy compared to non-Hispanic White patients overall (AIRR = 0.83, 95% CI = 0.72, 0.95) and in strata for stage I (AIRR = 0.74, 95% CI = 0.64, 0.87) or clear cell subtype (AIRR = 0.57, 95% CI = 0.42, 0.77). Hispanic patients had similar overall rates of nephrectomy as non-Hispanic White patients (AIRR = 1.16, 95% CI = 0.98, 1.37) and higher rates among those with clear cell RCC (AIRR = 1.40, 95% CI = 1.01, 1.96). Black patients had lower risk of recurrence (AHR = 0.61, 95% CI = 0.41, 0.92) relative to non-Hispanic White patients with no other racial-ethnic differences in outcomes in multivariable models.ConclusionIn the equal access MHS, there were some significant variations in rates of nephrectomy between racial-ethnic groups overall and among patient subgroups by tumor stage and histology. Despite observed lower surgery rates among non-Hispanic Black patients, the risk of recurrence or survival was lower or equal as compared to non-Hispanic White patients with non-metastatic RCC. Further research on factors other than access to care that may explain the differences in treatment and outcomes among racial-ethnic groups is needed.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251334455"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Potential Biological Roles and Clinical Significance of Anaphase-Promoting Complex Subunit 1 in Colorectal Cancer. 结直肠癌后期促进复合体亚基1的潜在生物学作用及临床意义。
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 Epub Date: 2025-04-14 DOI: 10.1177/10732748251330059
Yi Chen, Yu-Xing Tang, Da-Tong Zeng, Jia-Ying Wen, Yan-Ting Zhan, Dong-Ming Li, Rong-Quan He, Zhi-Guang Huang, Yu-Zhen Chen, Qiu-Yu Wei, Gang Chen, Yu-Lu Tang, Hui Li
{"title":"The Potential Biological Roles and Clinical Significance of Anaphase-Promoting Complex Subunit 1 in Colorectal Cancer.","authors":"Yi Chen, Yu-Xing Tang, Da-Tong Zeng, Jia-Ying Wen, Yan-Ting Zhan, Dong-Ming Li, Rong-Quan He, Zhi-Guang Huang, Yu-Zhen Chen, Qiu-Yu Wei, Gang Chen, Yu-Lu Tang, Hui Li","doi":"10.1177/10732748251330059","DOIUrl":"https://doi.org/10.1177/10732748251330059","url":null,"abstract":"<p><p>BackgroundAnaphase-promoting complex subunit 1 (ANAPC1) is a regulator of cellular mitosis and an important factor in tumorigenesis. To date, a comprehensive assessment of the potential role, biological behaviours, and clinical significance of ANAPC1 in colorectal cancer (CRC) is still lacking.Materials and methodsThis study integrated 2329 mRNA expression data, single-cell RNA sequencing (scRNA-seq), and internal immunohistochemistry of 416 tissue samples to comprehensively evaluate the abnormal expression pattern of ANAPC1 in CRC. It also incorporated evidence from immune infiltration analysis, functional enrichment analysis, and weighted gene co-expression network analysis to explore the biological behaviour of ANAPC1 in CRC. In addition, in vitro cell biology experiments such as real-time polymerase chain reaction (RT-PCR), western blot (WB), cholecystokinin 8 (CCK-8), wound healing, cell cycle, and apoptosis assays were conducted to verify the potential effect of ANAPC1 on CRC cells.ResultsANAPC1 mRNA was significantly overexpressed in CRC tissue (SMD = 2.07, 95% CI 1.59-2.55, <i>P</i> < .05) and malignant epithelial cells (<i>P</i> < .05). Validation at the protein level similarly confirmed the overexpression of ANAPC1 in CRC tissue (<i>P</i> < .05). ANAPC1 in CRC may play a role in abnormal ribosome biogenesis, DNA replication, ATP-dependent activity acting on DNA, nuclear division, chromosome segregation, and other pathways. In vitro experiments demonstrated that HCT-116 cells with ANAPC1 knockdown had reduced proliferation and migration abilities, increased cell apoptosis rate, and altered cell cycle distribution. In addition, CRC patients with low ANAPC1 expression were more likely to benefit from treatment with immune checkpoint inhibitors. ANAPC1 was significantly downregulated in malignant epithelial cells of CRC treated with PD-1 inhibitors (<i>P</i> < .05).ConclusionANAPC1 may have a positive impact on the development of CRC by being involved in pathways related to DNA replication, chromosome segregation, and ribosomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330059"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma. 体重指数(BMI)对晚期透明细胞肾癌患者接受全身抗癌治疗的临床结果的影响
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 Epub Date: 2025-03-17 DOI: 10.1177/10732748251317681
John Greene, Zhe Wang, Benjamin H L Harris, David Dodwell, Simon R Lord
{"title":"The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma.","authors":"John Greene, Zhe Wang, Benjamin H L Harris, David Dodwell, Simon R Lord","doi":"10.1177/10732748251317681","DOIUrl":"10.1177/10732748251317681","url":null,"abstract":"<p><p>IntroductionObesity is a risk factor for the development of renal cell carcinoma (RCC), however observational studies have suggested patients with RCC receiving systemic anti-cancer therapy (SACT) and BMI ≥25 kg/m<sup>2</sup> may have a better prognosis than patients with a normal or low BMI, a phenomenon often referred to as the obesity paradox.MethodsThe impact of BMI on survival outcomes in patients with advanced clear cell RCC receiving SACT within the National Health Service (NHS) in England between 2010 and 2018 was investigated. A retrospective analysis was performed using the SACT dataset from NHS-England.ResultsA total of 1034 patients were included. The majority of patients commenced treatment with oral SACT, pazopanib (53.3%) and sunitinib (43.7%). Median overall survival for patients with BMI ≤25 kg/m<sup>2</sup> was 12.6 months (95% CI; 10.1-14.4) and 17.9 months (15.4-20.0) for patients with BMI ≥25 kg/m<sup>2</sup> (<i>P</i> < .001). The association between BMI and improved survival was greatest in the first year of commencing SACT with the adjusted mortality rate of 68.9% for patients with BMI less than 25 kg/m<sup>2</sup> compared to 48.6% for patients with BMI greater than 25 kg/m<sup>2</sup> (rate ratio .77, .63 to .93).ConclusionA high BMI compared to a normal or low BMI was associated with improved survival in patients with metastatic RCC who were predominantly treated with oral SACT. Improved survival in obese patients with advanced RCC may be associated with improved response to systemic targeted therapies.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251317681"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
National Cancer Registries in Bangladesh and Social Determinants of Health: Challenging Cancer Disparities. 孟加拉国国家癌症登记和健康的社会决定因素:挑战癌症差异。
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 DOI: 10.1177/10732748251323757
Jabed Iqbal
{"title":"National Cancer Registries in Bangladesh and Social Determinants of Health: Challenging Cancer Disparities.","authors":"Jabed Iqbal","doi":"10.1177/10732748251323757","DOIUrl":"10.1177/10732748251323757","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251323757"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143525028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge of Human Papillomavirus, Risk Factors and Screening for Cervical Cancer Among Women in Ghana. 加纳妇女对人乳头瘤病毒、危险因素和宫颈癌筛查的了解。
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 DOI: 10.1177/10732748251323765
Yvonne Nartey, Kwabena Amo-Antwi, Betty Osei-Ntiamoah, Philip C Hill, Edward T Dassah, Richard H Asmah, Kofi M Nyarko, Ramatu Agambire, Thomas O Konney, Joel Yarney, Nelson Damale, Brian Cox
{"title":"Knowledge of Human Papillomavirus, Risk Factors and Screening for Cervical Cancer Among Women in Ghana.","authors":"Yvonne Nartey, Kwabena Amo-Antwi, Betty Osei-Ntiamoah, Philip C Hill, Edward T Dassah, Richard H Asmah, Kofi M Nyarko, Ramatu Agambire, Thomas O Konney, Joel Yarney, Nelson Damale, Brian Cox","doi":"10.1177/10732748251323765","DOIUrl":"10.1177/10732748251323765","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer ranks as the fourth most common cancer among women, with 662,301 new cases and 348,874 deaths reported in 2022. The majority of the disease burden occurs in low- and middle-income countries. In Ghana, there were 3072 new cases and 1815 deaths reported in 2022. While human papillomavirus (HPV) infection, a key cause for cervical cancer, resolves in most individuals, it can progress to cancer in some. This has led to research into other factors that may, in conjunction with HPV, increase the risk of cervical cancer progression. Improving knowledge of HPV, risk factors, and screening will be important in reducing the burden of cervical cancer. In this study, we investigate the knowledge on HPV, risk factors, and cervical screening among women in Ghana.</p><p><strong>Methods: </strong>A hospital-based case-control study was conducted among women aged 18 to 95 years. This involved Ghanaian women diagnosed with cervical cancer and hospital controls. Data were collected using a structured questionnaire, and basic descriptive analyses were performed.</p><p><strong>Results: </strong>Results from the 206 cases and 230 controls revealed limited knowledge about HPV and its role in cervical cancer development, with minimal disparity between women with (2.4%) and without (6.5%) cervical cancer. The majority of participants lacked awareness of HPV transmission (95.9%), and awareness of HPV vaccination was low (3.5%). Barriers to HPV vaccination included insufficient awareness about HPV, limited access to vaccination centers, and cost concerns. Respondents expressed a preference for educational programs delivered through church, radio, and television channels.</p><p><strong>Conclusions: </strong>Knowledge of HPV, risk factors, and cervical screening was found to be very low among Ghanaian women. These findings underscore the need for a comprehensive cervical cancer educational initiative within Ghana's national cervical cancer control policy to mitigate the disease's impact.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251323765"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychotherapeutic Applications of the SASB Cluster Analysis of Intrapsychic Behaviors in Women With Breast Cancer: A Step by Step Approach. SASB聚类分析在乳腺癌患者心理内行为的心理治疗应用:一步一步的方法。
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 Epub Date: 2025-03-17 DOI: 10.1177/10732748241302868
Anna Vespa, Roberta Spatuzzi, Paolo Fabbietti, Maria Velia Giulietti
{"title":"Psychotherapeutic Applications of the SASB Cluster Analysis of Intrapsychic Behaviors in Women With Breast Cancer: A Step by Step Approach.","authors":"Anna Vespa, Roberta Spatuzzi, Paolo Fabbietti, Maria Velia Giulietti","doi":"10.1177/10732748241302868","DOIUrl":"10.1177/10732748241302868","url":null,"abstract":"<p><p>BackgroundThis study describes the approach and phases of psychotherapeutic interventions in women with breast cancer on the basis of a personality cluster analysis performed using the Structural Analysis of Social Behavior (SASB) Model by Lorna S. Benjamin.MethodsThe SASB Model is a tool for diagnosing and planning the stages of psychotherapeutic intervention. Therefore, based on the cluster analysis of the intrapsychic problems of the 2 different profiles SASB-Love and Autonomy and SASB-Control and Hate Traits, it was possible to describe the phases and methods of the psychotherapeutic SASB intervention for each profile and the most suitable therapeutic approaches.ResultsThe results of the analysis, based on the intrapsychic profile derived from the SASB model and distributed along a continuum, indicate the need for specific psychotherapeutic interventions. Although some common intrapsychic issues were identified, their intensity varied across individuals, suggesting that tailored therapeutic approaches are necessary for each patient. The identified intrapsychic profiles, characterized by passive adaptation, low self-affirmation, and self-criticism, highlight the importance of facilitating self-contact, enhancing self-awareness, and promoting the elaboration and integration of emotional experiences.ConclusionIn this context, a targeted psychotherapeutic treatment aimed at fostering self-affirmation and reducing self-criticism can help women with breast cancer to transform their approach to dealing with their condition, leading to more effective adaptation and improved quality of life.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241302868"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Spanish Language Outreach on Multi-Target Stool DNA Test Adherence in a Federally Qualified Health Center in the United States. 西班牙语外展对美国联邦合格卫生中心多目标粪便DNA检测依从性的影响。
IF 2.5 4区 医学
Cancer Control Pub Date : 2025-01-01 Epub Date: 2025-05-14 DOI: 10.1177/10732748251343334
Mallik Greene, Timo Pew, A Burak Ozbay, Juliana Vanessa Rincón López, Durado Brooks, Jordan Karlitz, Martha Duarte
{"title":"Impact of Spanish Language Outreach on Multi-Target Stool DNA Test Adherence in a Federally Qualified Health Center in the United States.","authors":"Mallik Greene, Timo Pew, A Burak Ozbay, Juliana Vanessa Rincón López, Durado Brooks, Jordan Karlitz, Martha Duarte","doi":"10.1177/10732748251343334","DOIUrl":"10.1177/10732748251343334","url":null,"abstract":"<p><p>IntroductionThe objective of the current study was to examine the impact of Spanish-language patient outreach and navigation services on adherence to initial colorectal cancer (CRC) screening with multitarget stool DNA (mt-sDNA) testing in a predominantly Spanish-speaking patient population receiving care at Federally Qualified Health Centers (FQHCs).MethodThis study included patients aged 45 years or older who identified as Hispanic from FQHCs in a California Health System who were new to mt-sDNA testing and shipped a Cologuard® collection kit between 10-1-2022, and 1-1-2024. Patient outreach was provided only in English prior to 1-22-2023 (pre-intervention period). From 1-23-2023, onward, patient outreach was offered in either English or Spanish based on the patients' preferred language selection (post-intervention period). Patients were classified into two subgroups: Spanish language preference (SLP) or non-Spanish language preference (NSLP). It was hypothesized that adherence would be greater in SLP patients when patient outreach was provided in Spanish compared to the NSLP.ResultsThe final sample comprised 20 341 Hispanic patients who met the study criteria, comprising 15 702 patients with SLP and 4639 with NSLP, stratified across pre- and post-intervention periods. Overall, adherence to initial mt-sDNA testing within 180 days following the index date was 51.4% for SLP patients and 41.3% for NSLP patients, with a significant post-intervention improvement observed after the intervention for SLP patients (47.1% to 52.7%, <i>P</i> < .001), compared to a non-significant improvement (40.7% to 41.4%, <i>P</i> = .713) among NSLP patients.DiscussionFollowing the introduction of Spanish-language patient outreach, adherence to mt-sDNA testing improved significantly among SLP patients. The preference of Hispanic individuals for stool-based tests, combined with the non-invasive nature of mt-sDNA testing, supports its suitability as a CRC screening option for this population.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251343334"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信